To the full analysis
Buyback calculator for Egetis Therapeutics
Egetis Therapeutics stock: key metrics
EGTX.STEgetis Therapeutics had an operating margin of −555.9% and a return on invested capital (ROIC) of −52.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | 100.0% | −142,557.4% | −142,559.0% |
| 2011 | no data | no data | no data |
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | −446.2% | −648.5% | −647.3% |
| 2018 | −197.2% | −327.9% | −301.3% |
| 2019 | −35.9% | −80.8% | −74.4% |
| 2020 | −355.4% | −438.7% | −440.5% |
| 2021 | −152.4% | −276.3% | −273.9% |
| 2022 | −533.8% | −880.4% | −842.2% |
| 2023 | −255.0% | −563.9% | −567.5% |
| 2024 | 74.8% | −714.5% | −745.3% |
| 2025 | 19.9% | −555.9% | −548.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | −11.1% | −10.2% | −10.4% |
| 2009 | −23.9% | −22.2% | −22.8% |
| 2010 | −54.4% | −51.4% | −44.8% |
| 2011 | −38.0% | −57.2% | −36.4% |
| 2012 | −62.8% | −39.4% | −56.0% |
| 2013 | −54.4% | −40.8% | −50.1% |
| 2014 | −53.4% | −55.8% | −46.8% |
| 2015 | −91.3% | −50.2% | −83.7% |
| 2016 | −9.8% | −13.9% | −9.6% |
| 2017 | −29.0% | −20.1% | −27.9% |
| 2018 | −38.8% | −27.9% | −35.1% |
| 2019 | −25.1% | −22.7% | −22.7% |
| 2020 | −28.4% | −83.8% | −20.0% |
| 2021 | −19.9% | −22.8% | −18.4% |
| 2022 | −37.4% | −40.7% | −33.8% |
| 2023 | −59.9% | −69.7% | −43.0% |
| 2024 | −69.7% | −84.7% | −43.4% |
| 2025 | −100.0% | −52.3% | −53.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2012)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.